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Abstract
Background: Clinical audits have reported considerable variability in COPD medical care and frequent
inconsistencies with recommendations. The objectives of this study were to identify factors associated with a better
adherence to clinical practice guidelines and to explore determinants of this variability at the the hospital level.
Methods: EPOCONSUL is a Spanish nationwide clinical audit that evaluates the outpatient management of COPD.
Multilevel logistic regression with two levels was performed to assess the relationships between individual and
disease-related factors, as well as hospital characteristics.
Results: A total of 4508 clinical records of COPD patients from 59 Spanish hospitals were evaluated. High variability
was observed among hospitals in terms of medical care. Some of the patient’s characteristics (airflow obstruction,
degree of dyspnea, exacerbation risk, presence of comorbidities), the hospital factors (size and respiratory nurses
available) and treatment at a specialized COPD outpatient clinic were identified as factors associated with a better
adherence to recommendations, although this only explains a small proportion of the total variance.
Conclusion: To be treated at a specialized COPD outpatient clinic and some intrinsic patient characteristics were
factors associated with a better adherence to guideline recommendations, although these variables were only
explaining part of the high variability observed among hospitals in terms of COPD medical care.
Keywords: Chronic obstructive pulmonary disease, Clinical audit, Medical care, Clinical practice guidelines,
Adherence to recommendations
Background
Chronic obstructive pulmonary disease (COPD) is one
of the most frequent reasons for seeking medical
attention and accounts for 10% of primary care and
30% of outpatient respiratory care visits [1]. Patients
with this condition have a high morbidity and mortal-
ity [2, 3]. For these reasons, there are a number of
clinical practice guidelines (CPG) aimed to systemize
medical care for COPD [4–7]. However, the real-life
implementation of these CPG is low [8, 9].
Clinical audits have emerged as an overarching tool to
measure the adequacy of clinical practice and feedback is be-
ing used to improve health care [10]. For more than 12 years,
some countries have been auditing the quality of their in-
hospital COPD management in a systematic way [11–13].
However, we have less evidence regarding outpatient care,
and the few existing studies only explored certain aspects,
such as the diagnosis or the prescription pattern, showing us
outpatient care is far from perfect [14–18] with considerable
variability in COPD medical care and frequent inconsisten-
cies with CPG recommendations.
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The EPOCONSUL study is the first national audit to
evaluate the adequacy of medical care according to
CPG in Spain in COPD patients treated at outpatient
respiratory clinics. The study confirmed significant
variations in adherence to CPG recommendations be-
tween centers [19]. The objective of our work has
been analyze the variability and to identify factors as-
sociated with adherence to current recommendations
for COPD clinical practice guidelines for outpatients
in Spain.
Methods
The methodology of the EPOCONSUL audit has been
extensively described elsewhere [19]. Briefly, the
COPD audit promoted by the Spanish Society of
Pneumology and Thoracic Surgery (SEPAR) was de-
signed to evaluate clinical practice as well as clinical
and organizational factors related to managing pa-
tients with COPD across Spain. It was designed as an
observational non-interventional cross-sectional
study. Recruitment was intermittent during the year
(May 2014–May 2015). Every 2 months each investi-
gator recruited clinical records of the first 10 patients
identified as diagnosed with COPD and seen in the
outpatient respiratory clinic. Subsequently, patients
identified were reevaluated to determine if they met
the inclusion/exclusion criteria described in Appendix
1. The sampling process was detailed in an epidemi-
ology flow chart and described in Appendix 2.
The information collected was historical in nature
for the clinical data of the last and previous visits, and
the information about hospital resources was
concurrent.
As described in the methodological research paper
[19], in order to evaluate the degree of current CPG
implementation of the main statements according to
the 2012 Spanish National Guidelines for COPD care
(GesEPOC) and the 2013 Global initiative for chronic
Obstructive Lung Disease (GOLD), we established ful-
filling ≥ 50% of criteria for good clinical practice eval-
uated in each category (clinical evaluation of the
patient, COPD evaluation and therapeutic interven-
tion) as the cut-off point.
From the 175 public hospitals in the National Health
System invited from the Spanish Society of Pneumol-
ogy and Thoracic Surgery, 59 participated (33.3%).
The estimated reference population for the EPOCON-
SUL study was 18,104,350 inhabitants, representing
39% of the Spanish population. The distribution of
hospitals in the different regions and the population
covered by those hospitals are detailed in Appendix 3
and participating investigators are included in
Appendix 4.
In order to compare hospitals, these were divided in two
types of center according to their size (small or large) as
measured by: the number of beds per center ≥ 500, the
number of inpatient respiratory beds ≥ 20, the number of
pulmonology staff members ≥ 5, and the number of
annual outpatient respiratory visits ≥ 10,000. All the
criteria are necessary to be considered large.
The protocol was approved by the Ethics Committee
of the Hospital Clínico San Carlos (Madrid, Spain; in-
ternal code 14/030-E). Additionally, according to
current research laws in Spain, the ethics committee
at each participating hospital evaluated and agreed to
the study protocol. The need for informed consent
was waived because ours is a clinical audit, beside the
non-interventional nature of the study, the anonymi-
zation of data and the need to blindly evaluate the
clinical performance. This circumstance was clearly
explained in the protocol, and the ethical committees
approved this procedure. To avoid modifications to
the usual clinical practice and preserve the blinding of
the clinical performance evaluation, the medical staff
responsible for the outpatient respiratory clinic was
not informed about the audit. Data was entered re-
motely at each participating location to a centrally-
controlled server.
Statistical analysis
Descriptive results are presented both at the patient
and hospital level. Qualitative variables were summa-
rized by their frequency distribution as well as quanti-
tative variables by their median, interquartile range
(IQR) and minimum–maximum. The differences be-
tween hospital resources and characteristics according
to size (small vs large) were evaluated using χ2 tests
for categorical data, while the non-parametric Mann-
Whitney test was used for continuous data. Signifi-
cance of variability by area/hospital was explored by
the Kruskal–Wallis or chi-square tests.
With regard to missing data, after performing data
cleansing to identify and correct missing and extremely
unlikely values, the data was included in the analysis as
missing information.
Three dependent variables were generated to evaluate
the degree of CPG implementation; criteria of good clin-
ical practice were categorized into: fulfilling three cri-
teria at the clinical evaluation, fulfilling four criteria at
the COPD evaluation, and fulfilling three criteria at the
therapeutic intervention.
The association between each independent variable
(patient characteristics, hospital resources and work
organization) and each of the dependent variables was
assessed by calculating the crude odds ratio (OR) via
multilevel bivariate regression analysis. Each multi-
level analysis included two levels: the individual or
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patient level (level 1), and the hospital level (level 2).
It was developed in four consecutive steps: (1) Model
1 (empty model) which included only the dependent
variable and the hospital-cluster effect; (2) random ef-
fects Model 2, which included the hospital variables;
(3) random effects Model 3, which included the pa-
tient variables; (4) random effects Model 4, which in-
cluded the patient and hospital variables in order to
obtain an overall multivariable model. Candidate pre-
dictors with a value of p < 0.10 in the univariate ana-
lysis were accepted for inclusion in the multivariate
analysis in model 2 and 3. Variables were removed
from the model when the p-value exceeded 0.10 and
were kept in the final model when less than 0.05. The
independent predictor variables included in Model 4
were those selected in the last step in Models 2 and 3.
The coefficients of the predictor variables were trans-
formed into OR, with 95% confidence intervals (CI).
The hospital cluster effect was evaluated and quanti-
fied by two indicators: 1) the intra-cluster correlation co-
efficient (ICC) which represents the proportion of the
variance attributable to the clustering effect and 2) the
median odds ratio (MOR). The MOR can be interpreted
as the median increased odds of reaching the outcome if
an individual was admitted to another hospital with a
greater risk of that outcome.
All analyses were performed using STATA 12.0 soft-
ware. Statistical significance was assumed as p < 0.05.
Results
A total of 17,893 clinical records of patients treated in
outpatient respiratory clinics were evaluated during the
study period and 5726 clinical records of patients pre-
sumably diagnosed with COPD were selected. Of them,
4508 patients were audited from 59 hospitals, for having
all the inclusion criteria and none of the exclusion cri-
teria. The sampling process was detailed in an epidemi-
ology flow chart and described in Appendix 2.
Center characteristics
The hospital characteristics and respiratory unit re-
sources are summarized in Table 1. Large hospitals
constituted 54% of centers. The majority participating
centers were public (93.2%), university hospitals
(83.1%) and had a pulmonary resident available
(67.8%). Although the larger hospitals had more staff,
the length of the outpatient follow-up visit was simi-
lar. There were few centers with a specialized COPD
outpatient clinic (47.5%) and outpatient respiratory
nursing clinic (45.8%), regardless of hospital size.
Audited patient characteristics and clinical conditions
The main characteristics of the patients evaluated are
presented in Table 2.
Adequacy of medical care according to CPG
Adherence to the main CPG statements is summarized
in Table 3. There was a significant variation between
hospitals, with a better adherence to the statements in
the clinical evaluation category, with three out of six cri-
teria fulfilled in 65.5% of the patients.
Adherence to CPG recommendations based on patient
and center characteristics
The bivariate association between adherence to the main
CPG statements and the variables related to hospital and
patient characteristics is summarized in Appendix 5. A
major number of the patient-level variables were associ-
ated with adherence, whereas the majority of center-
level variables were not.
Multilevel variability analysis of adherence to CPG
recommendations
For the adherence to the statements in the clinical
evaluation category, fulfillment of at least three criteria,
the percentage of the total variability attributable to the
hospital-cluster effect was 36%. The empty model ex-
hibited a significant cluster effect (ICC = 0.36) and clus-
ter heterogeneity (MOR = 3.73). In the adjusted model,
being an active smoker, having a Charlson index ≥ 3,
undergoing ≥ 1 hospitalization for COPD in the past
year and being treated at a specialized COPD out-
patient clinic was positively associated. Only one vari-
able linked to the hospital level (large hospital) was
retained in the model as a predictor, but was unfavor-
able (Table 4). The inclusion of all predictors further
reduced the residual between-hospital cluster variabil-
ity. The ICC and MOR dropped to 0.31 and 3.26, re-
spectively (Table 4). Some unrecorded values (COPD
phenotype missing) showed significant associations,
which is naturally open to interpretation.
For COPD evaluation category, fulfillment of at least
four criteria, the empty model displayed an ICC of 0.30
and a MOR of 3.13 (Table 4). In the adjusted model, an
age of ≤ 55 years, FEV1 < 50%, dyspnea ≥ 2 MRC-m and
being treated at a specialized COPD outpatient clinic
were positively associated with better adherence to
CPG recommendations. However, being male and hav-
ing a Charlson index ≥ 3 were retained as predictors of
worse adherence. Some unrecorded values (COPD
phenotype missing, dyspnea missing, or level of
dyspnea not referred to) showed a significant negative
association. Only one variable linked to the hospital
level (i.e. respiratory ward availability) was retained as a
predictor of better adherence. The inclusion of this
predictor further reduced the between-hospital cluster
variability. The ICC and MOR dropped to 0.24 and
2.67, respectively.
Calle Rubio et al. Respiratory Research  (2017) 18:200 Page 3 of 14
For therapeutic intervention category, fulfillment of at
least three criteria, the empty model displayed an ICC of
0.52 and a MOR of 6.09. A Charlson index ≥ 3, undergo-
ing ≥ 1 hospitalizations in the past year, being treated at
a specialized COPD outpatient clinic, and outpatient re-
spiratory nursing clinic availability were associated with
better adherence to the recommendations. Meanwhile,
being male, being ≤ 55 years old and being a university
hospital were all associated with worse adherence. The
inclusion of these predictors further reduced the
between-hospital cluster variability. The ICC and MOR
dropped to 0.44 and 4.74, respectively (Table 4).
Discussion
The present study constitutes one of the few research
papers in the literature that analyze the variability in ad-
herence to current recommendations for COPD clinical
practice guidelines for outpatients in Spain. In our ana-
lysis, we aimed to study the variables associated with this
variability.
This study shows that accounting for the hospital cluster
effect, the patient-level and hospital-level predictor vari-
ables, partly reduced the unexplained between-hospital
variation in adherence. Additionally, it identified a number
of variables as predictors of better adherence at the pa-
tient and hospital levels. Most predictors were linked to
patient characteristics (patient-level) and the type of re-
spiratory clinic in which the patient was treated (general
clinic or specialized COPD outpatient clinic).
Being treated at a specialized COPD outpatient
clinic was associated with a higher likelihood of ad-
herence to guidelines in the three categories evalu-
ated, and was considered to be of greater importance,
compared with the cluster effect, in explaining the
between-hospital outcome variations. This is an
Table 1 Characteristics of the participating hospitals and resources of the respiratory units
All Small hospital Large hospital P†
Number of participating hospitals, n 59 27 32
Public hospital (%) 93.2 85.2 100 0.039
University hospital (%) 83.1 63 100 < 0.001
Beds per center ≥ 500 (%) 62.7 18.5 100 < 0.001
Beds per center, median (P25–75) 651 (349–943) 332 (231–436) 903 (702–1199) < 0.001
Hospital with a respiratory ward (%) 83.1 63 100 < 0.001
Number of inpatient respiratory beds ≥ 20 (%) 83.7 52.9 100 < 0.001
Number of pulmonology staff members ≥ 5 (%) 81.4 59.3 100 < 0.001
Number of pulmonology staff members, median (P25–75) 10 (5–13) 5 (2–8) 13 (10–16) < 0.001
Pulmonology residents available (%) 67.8 33.3 96.9 < 0.001
Number of annual outpatient respiratory visits, median (IQR) 15,447 (12004–25,680) 12,004 (4355–13,556) 23,985 (16070–27,838) < 0.001
Number of annual outpatient respiratory visits ≥ 10,000 (%) 81.4 59.3 100 < 0.001
≥ 15 min of follow-up at general outpatient respiratory visit (%) 44.1 48.1 40.6 0.562
Specialized COPD outpatient clinic available (%) 47.5 40.7 53.1 0.343
≥ 15 min of follow-up at specialized COPD outpatient visit (%) 64.4 74.1 56.3 0.154
Outpatient respiratory nursing clinic availability (%) 45.8 44.4 46.9 0.852
Functional respiratory laboratory available (%)
- Spirometry 100 100 100 1
- Diffusing capacity 100 100 100 1
- Plethysmography 100 100 100 1
- Respiratory muscle strength 84.7 66.7 100 < 0.001
- 6MWT available 94.9 88.9 100 0.090
- Cardiopulmonary exercise testing available 62.7 40.7 81.3 0.001
Inhalation technique educational program available (%) 30.5 15.6 48.1 0.007
Respiratory rehabilitation program available (%) 74.6 66.7 81.3 0.2
- Hospital-based 61.4 61.1 61.5 0.617
- Home-based 6.8 11.1 3.8
- Mixed 31.8 27.8 34.6
Data are presented as median (CI 95%), unless stated otherwise. Dichotomous variables are expressed as number and/or percent. p† calculated by the
Kruskal–Wallis or Chi-square test, depending on the nature of the variable
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Table 2 Clinical characteristics of the audited cases
Patients (N = 4508) Hospitals (N = 59) p†
N % or median (IQR) Median IQR
Sex (male), (%) 4.508 86 87.5 82.1–93.2 < 0.001
Age (years), median (P25–75) 4.508 69.7 (63–77.7) 70 69–72 < 0.001
≤ 55 (%) 8.5 8.2 5.8–11.7
56–69 (%) 38.7 38.1 30–42.6
≥ 70 (%) 52.8 53.3 47.1–61.7
Pack-years, median (P25–75) 4.508 47 (34–70) 45 40–51 < 0.001
Active smokers, (%) 4.508 23.1 22 18–29 < 0.001
BMI kg/m2, median (P25–75) 4.508 28.0 (24.4–31.1) 27.8 26.6–28.5 0.03
≤ 21 (%) 7.1 6.7 4.1–9.2
22–29 (%) 60.8 58.8 56.1–64
≥ 30 (%) 32.1 31.4 26.2–37.7
Charlson index, median (P25–75) 4.508 2 (1–4) 2 2–3 < 0.001
≥ 3 (%) 44.9 44.5 40–56.6
Dyspnea (MRC-m) 4.508 < 0.001
0 + 1 (%) 27.3 23.8 11.6–44.5
≥ 2 (%) 41.4 38.3 28.3–54
Missing (%) 13.2 8.9 1.6–21.6
Level of dyspnea not referred to (%) 18.1 11.6 3.3–30
CAT questionnaire >10, (%) 869 62.4 64 47.9–83.8 < 0.001
Chronic bronchitis criteria, (%) 4.508 41.7 41 28.3–51 < 0.001
Chronic colonization, (%) 4.508 6.0 5 3.2–8.3 < 0.001
Symptoms suggestive of asthma,(%) 4.508 26.5 18.3 10.8–35 < 0.001
% FEV1, median (P25–75) 4.508 50 (37–63) 51 47–54 0.03
< 50% 49.1 45.5 41.5–53.3
50–64% 28 28.5 22.3–31.7
≥ 65% 22.9 23.8 15–30
Number of moderate/severe exacerbations in the last year, median (P25–75) 3.196 1.1 (0–2) 1 0–1 0.03
Number of hospital admissions in the last year, median (P25–75) 4508 0.5 (0–1) 0 0–0 0.03
BODE value, median (P25–75) 632 3.9 (3–5) 4.5 3–5.5 < 0.001
GOLD group 985 < 0.001
A (%) 22.7 14.3 0–25.9
B (%) 18.7 16.7 0–24.1
C (%) 18.7 20 9.8–33.3
D (%) 39.9 40 23.5–55.6
GesEPOC Phenotype 4.508 < 0.001
- Non-exacerbator, (%) 27.5 24.4 11.4–28
- Exacerbator, (%) 18.8 15.7 3.4–22
- Missing, (%) 53.7 52.3 44–58.9
LAMA monotherapy, (%) 4.391 10.0 10 4.8–15.3 0.03
LAMA-LABA combination, (%) 4.391 22.7 20.3 14.5–27.9 < 0.001
LABA+ ICS combination, (%) 4.391 7.7 6.7 3.4–9.8 0.03
Triple therapy (LAMA + LABA + CSI), (%) 4.391 49.1 50.8 39.3–60.3 < 0.001
Long-term oxygen therapy, (%) 4.508 26.6% 25 17.1–33.3 0.03
Home ventilation, (%) 4.508 7.5% 5 2.5–11.6 < 0.001
Respiratory rehabilitation, (%) 4.508 9 5 0–11.8 < 0.001
Respiratory care follow-up (years), (%) 4.508 4 (2–7) 4 3.5–5 0.03
Dichotomous variables are expressed as n and percentage. Average value expressed as median (P25–75). The variability was expressed using the interquartile range (IQR) of
median. †Calculated for the variability between centers using test de Kruskal–Wallis or chi-square test, depending on the nature of the variable
Abbreviations: LABA long-acting beta-2 agonists, LAMA long-acting antimuscarinic agents, ICS inhaled corticosteroids, GOLD Global Initiative for Chronic Obstructive Lung
Disease, GesEPOC Spanish National Guidelines for COPD, CAT COPD Assessment Test
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interesting result, since less than half of the centers
had specialized COPD outpatient clinics. In addition,
the time available at specialized COPD outpatient
clinics to treat the patient was the same as the gen-
eral outpatient respiratory visit and there was no sup-
port nurse. Consequently, this could be considered a
proxy for the experience, knowledge and interest of
department physicians in the management of COPD
patients.
Also, some unrecorded values (COPD phenotype miss-
ing and level of dyspnea missing) showed a statistically
significant negative association, which are naturally open
to interpretation.
The clinical COPD phenotype according to the
Spanish National Guideline for COPD (GesEPOC) was
collected in 46.3% of the audited patients.
Only 2 (outpatient respiratory nursing clinic and a
respiratory ward availability) of the 46 hospital-level
variables examined were retained in the model associ-
ated with a higher likelihood of implementing CPG
recommendations. On the contrary, being a university
hospital or large hospital were negatively associated
factors. Nevertheless, given the small amount of clus-
ter variability left unexplained in the analysis, it is un-
likely that relevant hospital-level variables were not
revealed. It’s possible that this finding is the result of a
relative small hospital sample size (N = 59). Thus,
medical care in COPD does not require complex in-
terventions and the majority of respiratory units of-
fered a functional respiratory laboratory. We must
consider the fact that this study did not include infor-
mation about work organization such as COPD clin-
ical management protocol availability or electronic/
digital information availability. It also did not include
the number of respiratory physicians or respiratory
nurses available in the area around the clinic or the
professional experience of treating physicians, which
might explain a proportion of the total variance due to
the center effect.
Our findings are similar to those of previous studies
that have demonstrated significant variability in the
processes of COPD care. In the European COPD
Audit [13], a considerable variability in recommenda-
tion guideline suitability was described and only hos-
pital characteristics were related to a minority of
indicators. The adherence to guidelines also varied
with hospital size, but the differences were small and
inconsistent. Previous studies have shown adherence
to clinical guidelines was a strong predictor of a favor-
able outcome. Roberts et al. [11] have suggested that a
Table 3 Adherence to recommendations (GOLD and GesEPOC) evaluated in the study and classified in three categories: clinical
evaluation of the patient, COPD evaluation and therapeutic interventions. The number of criteria or quality standards fulfilled was
analyzed in each category





(N = 4.508) %
Hospitals





1. Was degree of dyspnea evaluated during current visit?
2. Was the number of hospital admissions in the last 12 months
collected during current visit?
3. Was the number of moderate or severe exacerbations in the
last 12 months collected during current visit?
4. Was current smoking habit information collected?
5. Was regular exercise data collected during current visit?
6. Are comorbidities identified in the clinical record?
6 criteria 18.3 14.6 0–100 < 0.001
>3 criteria 65.5 70 11.7–100 < 0.001
≤3 criteria 34.5 30 0–88.3 < 0.001
COPD evaluation category
1. Alfa-1-antitrypsin serum level determination available?
2. COPD severity defined in the report?
3. COPD GOLD type defined in the report?
4. COPD phenotype according to GesEPOC defined in the report?
5. 6MWT carried out on any occasion?
6. Diffusion capacity measured on any occasion?
7. Lung volumes measured on any occasion?
8. Chest CT scan carried out on any occasion in exacerbator
phenotype?
8 criteria 1.5 0 0–14.6 < 0.001
> 4 criteria 30.1 27 0–89.3 < 0.001
≤ 4 criteria 69.9 73 10.7–100 < 0.001
Therapeutic intervention category
1. Is treatment adherence evaluated in any way?
2. Is inhalation technique evaluated in any way?
3. Is Pneumococcal vaccination recommended?
4. Is exercise advised during the visit?
5. Have arterial blood gases been measured on any occasion
in patients on long-term oxygen therapy?
6. Is a specific intervention for smoking cessation for active smokers offered?
6 criteria 9.3 3.3 0–45.1 < 0.001
> 3 criteria 22.4 12.5 0–100 < 0.001
≤ 3 criteria 77.6 87.5 0–100 < 0.001
Dichotomous variables are expressed as n and percentage. The variability between centers was expressed using the inter-hospital range (min–max).
p† was calculated for the variability between centers using the Kruskal–Wallis or Chi-square tests, depending on the nature of the variable
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Table 4 Multilevel logistic regression models of the variability in adherence to good clinical practice criteria for three categories:








Adherence to good clinical practice criteria in clinical evaluation (≥3 criteria fulfilled)
Empty model 1 0.36670 3.73040
Model 2: center variables1 0.31866 3.26487
Model 3: patient variables2 0.36831 3.74755
Full model 4
(center and patient)




Active smokers 1.32 (1.10–1.58) 0.003
Charlson index ≥3 1.35 (1.15–1.59) < 0.001
Number of hospital admissions
in the last year ≥1
6.33 (5.02–7.98) < 0.001
GesEPOC phenotype
Not exacerbator (reference)
Exacerbator 0.79 (0.61–1.101) 0.063
Missing 0.36 (0.29–0.44) < 0.001
To be taken care in specialized
COPD outpatient clinic)
2.10 (1.56–2.72) < 0.001
1: included variables in the final center model: large hospital and outpatient respiratory nursing clinic available
2: included variables in the final patient model: active smokers, Charlson index ≥3, number of hospital admissions
in the last year ≥1, to be taken care in specialized COPD outpatient clinic and GesEPOC phenotype exacerbator.
Adherence to good clinical practice criteria in COPD evaluation (≥4 criteria fulfilling)
Empty model 1 0.30343 3.13266
Model 2: center variables1 0.26684 2.83994
Model 3: patient variables2 0.29100 3.02953
Full model 4 (center and patient) 0.24413 2.67316 Respiratory ward not available (reference)
Respiratory ward < 20 beds 7.09 (2.53–9.90) < 0.001
Respiratory ward ≥20 beds 3.00 (1.37–6.60) 0.006
Age≤ 55 1.58 (1.19–2.09) 0.001
Sex (male) 0.77 (0.61–0.96) 0.022
Charlson index ≥3 0.80 (0.68–0.94) 0.008
FEV1 < 50% 1.68 (1.42–1.99) < 0.001
Dyspnea (MRC-m)
0–1 (reference)
≥ 2 1.39 (1.13–1.72) 0.002
Missing 0.69 (0.51–0.93) 0.017
Level of dyspnea not referred to 0.65 (0.49–0.86) 0.003
GesEPOC phenotype
Non-exacerbator (reference)
Exacerbator 1.16 (0.93–1.44) 0.185
Missing 0.17 (0.14–0.21) < 0.001
Treatment at a specialized COPD outpatient clinic 3.25 (2.49–4.23) < 0.001
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hospital’s resources are potential components of the
unexplained variation in outcomes. A greater number
of medical and nursing staff was identified as a
protective factor for intra-hospital mortality. In
AUDIPOC Spain [12, 20], the large hospital COPD
volume and the number of COPD patients admitted to
the hospital the year prior to admission was identified
as a predictor of a favourable outcome.
In our study, a large component of center-related vari-
ance remained unexplained, suggesting that the clinical
profile of patients included in the study also varied
markedly among hospitals. It is important to remember
that recommendation guidelines are evidence-based and
aimed to systemize medical care, but the clinical presen-
tation of COPD is variable [21].
Our study has several strengths and limitations. The
main strength is its sample size that accounts for 39%
of the Spanish population. Nevertheless, the limita-
tions to be considered are the fact that the selection of
participating centers was not random and hospital
participation was voluntary based on their interest to
participate. Also, clinical records were used as the
data source, so some missing and inconsistent values
were unavoidable. Despite these limitations, we
believe that this dataset represents the largest avail-
able comparative survey of Spanish centers.
Conclusions
High variability was observed among hospitals in terms
of medical care. Some of the patient’s characteristics (air-
flow obstruction, degree of dyspnea, exacerbation risk,
presence of comorbidities) and the type of respiratory
clinic in which the patient was treated (specialized
COPD outpatient clinic) were identified as factors asso-
ciated with a better adherence to recommendations,
though a great part of the variability among center can-
not be explained. This suggests that there is a significant
inconsistency among centers in the implementation of
clinical guidelines.
This information must be accounted for by health care
professionals and administrators, in order to establish
better clinical practice by means of the medical care in
the specialized COPD outpatient clinic and the imple-
mentation of evidence-based best clinical practice guide-
lines that could facilitate a uniform approach to COPD
patients as outpatients, thereby both improving patient
outcomes and optimizing medical resources.
Table 4 Multilevel logistic regression models of the variability in adherence to good clinical practice criteria for three categories:








1: variables included in the final center model: in-patient respiratory clinic ≥20 present and specialized COPD outpatient clinic available.
2: variables included in the final patient model: age≤ 55, gender (male), Charlson index ≥3, FEV1 < 50%, dyspnea,
GesEPOC exacerbator phenotype and being treated in specialized COPD outpatient clinic.
Adherence to good clinical practice criteria in therapeutic intervention (≥3 criteria fulfilled)
Empty model 1 0.52169 6.09155
Model 2: center variables1 0.46935 5.08927
Model 3: patient variables2 0.49994 5.64024
Full model 4 (center and patient) 0.44731 4.74211 University hospital 0.26 (0.08–0.85) 0.026
Outpatient respiratory nursing clinic availability 3.69 (1.50–9.11) 0.005
Age≤ 55 0.60 (0.42–0.86) < 0.005
Sex (male) 0.72 (0.55–0.93) 0.014
Charlson index ≥3 1.19 (0.99–1.42) 0.062
Number of hospital admissions in the last year ≥1 1.71 (1.38–2.11) < 0.001
GesEPOC phenotype
Non-exacerbator (reference)
Exacerbator 0.90 (0.71–1.15) 0.404
Missing 0.36 (0.29–0.46) < 0.001
Treatment at a specialized COPD outpatient clinic 2.61 (2.01–3.40) <0.001
1: variables included in the final center model: university hospital and outpatient respiratory nursing clinic availability
2: variables included in the final patient model: age≤ 55, gender (male), Charlson index ≥3, number of hospital admissions
in the last year ≥1, GesEPOC exacerbator phenotype and being treated in specialized COPD outpatient clinic
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Fig. 1 The sampling process is described in a STROBE flow chart
Table 5 The inclusion criteria and exclusion criteria
The inclusion criteria - patients aged ≥40 years
- smokers or ex-smokers (of at least 10 pack-years)
- COPD diagnosed on the basis of spirometric tests (FEV1/FVC post-bronchodilation < 0.7 or FEV1/FVC pre-bronchodilation
< 0.7 and FEV1≥ 80%, if there is no bronchodilation reversibility testing available
The exclusion criteria - lack of follow-up for at least 1 year in a respiratory outpatient clinic
- participating in a clinical trial
Appendix 1
Appendix 2
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Appendix 4
Participants investigators in EPOCONSUL study
Andalucía: Jose Luis Rojas Box, H. de Alta Resolución
de Écija, Sevilla. Jose Domingo Garcia Jimenez, H. de
Alta Resolución de Utrera, Sevilla. Adolfo Domenech del
Rio, Ana Muñoz. H. Carlos Hayas, Málaga. Antonia Soto
Venegas, H. San Juan de la Cruz, Úbeda, Jaén. Aurelio
Arnedillo Muñoz. H. U. Puerta del Mar, Cádiz. Agustín
Valido Morales. H. Virgen de Macarena. Sevilla. Jose
Velasco Garrido, Carlos Rueda Ríos, Macarena Arroyo
Varela H. Virgen de la Victoria. Málaga. Francisco
Ortega Ruiz, Eduardo Marquez Martin, Carmen Calero
Acuña, H. Virgen del Rocio, Sevilla. Francisco Luis
Garcia Gil, H. U Reina Sofia, Córdoba.
Aragón: Joaquin Carlos Costan Galicia, H. Clínico U.
Lozano Blesa, Zaragoza. Ana Boldova Loscertales, H.
Royo Villanova, Zaragoza.
Asturias: Cristina Martinez González, Rosirys Guzman
Taveras, H. U. Central de Asturias, Oviedo.
Murcia: Juan Luis De la Torre Alvaro, H. U Santa
Lucia, Cartagena, Mª Jesus Avilés Ingles, H. General U.
Reina Sofia, Murcia. Rubén Andújar Espinosa, H.U.
Virgen de la Arrixaca, Murcia.
Canarias: Juan Manuel Palmero Tejera, Juan Marco
Figueira Conçalves, H.U. Nuestra Señora de la
Candelaria, Santa Cruz de Tenerife.
Cantabria: Ramon Agüero Balbín, Carlos Amado
Diago, Beatriz Abascal Bolado.
H. Marqués de Valdecilla, Santander. Juan Luis Garcia
Rivero, Marcelle Cohen Escovar, H. de Laredo,
Santander.
Castilla y la Mancha: Francisco Javier Callejas
González. Complejo hospitalario universitario de
Albacete, Albacete. Angel Ortega Gonzalez. H Nuestra
Señora del Prado, Talavera de la Reina, Toledo. Rosario
Vargas Gonzalez, H. Virgen de la Luz, Cuenca.
Encarnación López Gabaldón, Raul Hidalgo Carvajal, H.
Virgen de la Salud, Toledo.
Castilla y León: Elena Bollo de Miguel, Silvia
Fernández Huerga, Complejo Hospitalario Universitario
de León. Ana Pueyo Bastida, Complejo Asistencial de
Burgos, Burgos. Jesus R Hernández Hernández, Ruth
Garcia García, H. Nuestra Señora de Sonsoles, Ávila.
Miguel Barrueco Ferrero, Marco López Zuibizarreta, E.
Consuelo Fernández, H. Universitario de Salamanca.
Cataluña: David De la Rosa Carrillo, H. Plató,
Barcelona. Jordi Esplugas Abós, Noelia Pablos Mateos, H.
Sant Joan de Déu, Martorell. Elena De Miguel Campos, H.
Sant Joan de Despi, Barcelona. Pablo Rubinstein, Hospital
General de Cataluña, Barcelona. Hernán Abraham
Manrique Chávez, H Sagrat Cor, Barcelona. Miriam
Barrecheguren, H. U. Vall d’Hebron, Barcelona.
Table 6 Participating hospitals and catchment population by Autonomous Community






Catchment population of the EPOCONSUL
study (%)
Andalucía 10 2.784.083 8.424.102 33
Aragón 2 597.000 1.346.293 44.3
Asturias 1 250.000 1.081.487 23.1
Islas Baleares 2 575.000 1.113.114 51.6
País Vasco 4 1.285.000 2.184.606 58.8
Islas Canarias 1 700.000 2.126.769 32.9
Cantabria 2 395.000 593.121 66.6
Castilla y la
Mancha
4 1.186.014 2.115.334 56
Castilla y León 4 1.119.086 2.558.463 43.7
Cataluña 5 1.657.000 7.539.618 22
Extremadura 1 273.977 1.109.367 24.7
Galicia 2 970.000 2.795.422 34.7
Madrid 11 3.484.995 6.489.680 53.7
Murcia 3 770.175 1.470.069 52.3
Navarra 1 517.020. 642.051 80.5
Valencia 6 1.540.000 5.117.190 30
TOTAL 59 18.104.350 46 .064 .635 39.3
Data are presented as Numbers. The percentages refer to the total population number
There was no participating hospital in La Rioja, the 17th Autonomous Community in Spain
Appendix 3
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Valencia: Carmen Aguar Benito, H. de Arnau de
Villanova, Valencia. Pablo Catalán Serra, H. de
Requena, Requena. Eusebi Chiner Vives. H. U. de San
Juan, Alicante. Juan Antonio Royo Prats. H. General de
Castellón, Castellón de la Plana. Cristina Sabater Abad,
Esther Verdejo Mengual, H. General Universitario de
Valencia. Eva Martínez- Moragon, H. Universitario Dr.
Peset, Valencia.
Extremadura: Francisca Lourdes Marquez Perez, H. U
Santa Cristina, Badajoz.
Galicia: Alberto Fernandez Villar, Cristina Represas
Represas, Ana Priegue Carrera, Complejo hospitalario de
Vigo. Marina Blanco Aparicio, Pedro Jorge Marcos
Rodriguez, H. U. Juan Canalejo, La Coruña.
Baleares: Federico Gonzalo Fiorentino, Mª Magdalena
Pan Naranjo, H. Son Espases, Palma de Mallorca. Antonia
Fuster Gomila, H. Sant Llatzer, Palma de Mallorca.
Madrid: German Peces Barba, Felipe Villar Alvarez,
Fundación Jimenez Diaz, Madrid. Carlos Jose Álvarez
Martinez, H. 12 de Octubre, Madrid. Juan Luis
Rodriguez Hermosa, J.L. Álvarez Sala-Walther, Juan
Rigüal Bobillo, Gianna Vargas Centanaro, H. Clinico San
Carlos, Madrid. José Andrés García Romero de Tejada,
H. U. Infanta Sof ía, San Sebastián de los Reyes, Madrid.
Javier Jareño, Sergio Campos Tellez. H. Central de la
Defensa, Madrid. Raul Galera Martinez, H. La Paz. Rosa
Mar Gómez Punter, Emma Vázquez Espinosa, H. La
Princesa, Madrid. Esther Alonso Peces, H. Principe de
Asturias, Alcalá de Henares, Madrid. Juan Manuel Diez
Piña, Raquel Pérez Rojo, H. U. de Móstoles, Madrid.
Luis Puente Maestu, Julia Garcia de Pedro. H. U.
Gregorio Marañón, Madrid. Soledad Alonso Viteri, H. U
de Torrejón, Torrejón de Ardoz, Madrid.
Navarra: Maria Hernandez Bonaga, Complejo Hospi-
talario de Navarra, Pamplona.
País Vasco: Maria Milagros Iriberri Pascual, H de
Cruces, Baracaldo. Myriam Aburto Barrenechea, H de
Galdakano. Sophe Garcia Fuika, Hospital Santiago
Apostol, Vitoria. Patricia Sobradillo Ecenarro, Hospital
Txagorritx, Basurto.
Table 7 Logistic regression bivariate analysis (adherence to good clinical practice criteria in three categories: clinical evaluation of
the patient, COPD evaluation and therapeutic interventions)
Patients Clinical evaluation
≥ 3 criteria fulfilled
OR (95%CI)
p Centers Clinical evaluation
≥ 3 criteria fulfilled
OR (95% CI)
p
Age (≤55 years) 1.01 (0.78–1.31) 0.89 Large hospital 0.44 (0.21–0.89) 0.024
Sex (male) 0.96 (0.78–1.17) 0.70 University hospital 0.32 (0.12–0.82) 0.018
Active smokers 1.25 (1.05–1.48) 0.011 Beds per center ≥500 0.57 (0.27–1.22) 0.152
Dyspnea (MRC-m) Respiratory ward not available Reference
0–1 Respiratory ward <20 beds 0.90 (0.24–3.32) 0.876
≥2 Reference Respiratory ward ≥20 beds 0.51 (0.19–1.35) 0.178





FEV1< 50% 1.24 (1.07–1.43) 0.004 Number of pulmonology
staff members ≥ 5
0.80 (0.35–1.86) 0.620
Charlson index ≥ 3 1.45 (1.25–1.69) <0.001 Pulmonology residents present 0.90 (0.41–1.99) 0.806
Number of hospital
admissions in the
last year ≥ 1
6.45 (5.16–8.07) <0.001 Number of annual outpatient respiratory visits
≥ 10,000
0.45 (0.17–1.19) 0.109




Exacerbator 1.26 (1.00–1.59) 0.048
Missing 0.40 (0.33–0.49) <0.001
Triple inhalation therapy 1.01 (0.87–1.17) 0.872 Specialized COPD outpatient
clinic available
1.07 (0.51–2.22) 0.850
Treatment at a specialized COPD
outpatient clinic
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Table 7 Logistic regression bivariate analysis (adherence to good clinical practice criteria in three categories: clinical evaluation of
the patient, COPD evaluation and therapeutic interventions) (Continued)
Patients Clinical evaluation
≥ 3 criteria fulfilled
OR (95%CI)
p Centers Clinical evaluation










Age (≤55 years) 1.68 (1.31–2.14) <0.001 Large hospital 1.25 (0.66–2.39) 0.484
Sex (male) 0.75 (0.61–0.92) 0.006 University hospital 1.16 (0.49–2.74) 0.729
Active smokers 1.01 (0.82–0.85) 0.824 Beds per center ≥500 1.65 (0.85–3.20) 0.136
Dyspnea (MRC-m) Respiratory ward not available Reference
0–1 Respiratory ward <20 beds 4.23 (1.39–12.86) 0.011
≥2 Reference Respiratory ward ≥20 beds 2.23 (0.96–5.19) 0.062





FEV1<50% 1.80 (1.55–2.08) <0.001 Number of pulmonology
staff members ≥5
1.44 (0.69–3.00) 0.324




1.30 (1.10–1.55) 0.002 Number of annual outpatient
respiratory visits ≥10,000
1.82 (0.78–4.25) 0.165





Exacerbator 1.38 (1.13–1.69) 0.001
Missing 0.16 (0.13–0.20) <0.001
Triple inhalation therapy 1.37 (1.18–1.60) <0.001 Specialized COPD outpatient
clinic available
1.77 (0.94–3.31) 0.073
Treatment at a specialized COPD
outpatient clinic














Age (≤55 years) 0.62 (0.44–0.87) 0.007 Large hospital 0.46 (0.16–1.25) 0.130
Sex (male) 0.79 (0.61–1.02) 0.074 University hospital 0.32 (0.08–1.17) 0.087
Active smokers 0.98 (0.80–1.20) 0.894 Beds per centre ≥500 0.78 (0.27–2.25) 0.656
Dyspnea (MRC-m) Respiratory ward not available Reference
0–1 Reference 0.26 (0.04–1.66) 0.158
≥2 1.10 (0.90–1.35) 0.317 Respiratory ward <20 beds 0.32 (0.08–1.19) 0.090




FEV1<50% 1.32 (1.07–1.63) 0.008 Number of pulmonology
staff members ≥5
0.41 (0.13–1.27) 0.125




1.83 (1.50–2.23) 0.000 Number of annual outpatient
respiratory visits ≥10,000
0.29 (0.08–1.06) 0.062
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